Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
Gastric residence systems comprising therapeutic agent formulations for sustained gastric release of therapeutic agents are disclosed, as well as methods for using such systems. The systems are characterized by use of a dispersant in the formulations, which improves the burst release characteristics and long-term release rate characteristics of the systems. Milling of therapeutic agent can also be performed to prepare agent particles of desired size.
1. A gastric residence system for administration to a patient, comprising:
a plurality of carrier polymer-agent components comprising:
a carrier polymer, wherein the carrier polymer comprises:
vinylpyrrolidone-vinyl acetate copolymer (VA64), wherein the carrier-polymer-agent components comprise about 5% to about 10% of vinylpyrrolidone-vinyl acetate copolymer (VA64); and
polycaprolactone, wherein the carrier polymer-agent components comprise about 50.5% to about 89% polycaprolactone;
a therapeutic agent or a pharmaceutically-acceptable salt thereof blended into the carrier polymer;
a dispersant comprising silica (SiO2), wherein the carrier-polymer-agent components comprise about 0.1% to about 1% of silica (SiO2);
an excipient, wherein the excipient comprises:
a release enhancer comprising poloxamer P407, wherein the carrier-polymer-agent components comprise about 1% to about 5% of poloxamer P407; and
a stabilizer, wherein the carrier-polymer-agent components comprise about 0.1% to about 2% of stabilizer;
wherein the carrier polymer-agent components are linked together by one or more coupling polymer components, wherein at least one of the one or more coupling polymer components is an elastomer;
wherein the gastric residence system is configured to have a compacted form in a container, suitable for administration orally or through a feeding tube; and an uncompacted form when released from the container;
wherein the gastric residence system is retained in the stomach for a residence period of between at least about 24 hours and about one month; and
wherein:
the system releases a therapeutically effective amount of the therapeutic agent over an effective release period; and
the system releases less than about 20% of the therapeutic agent or pharmaceutically-acceptable salt thereof within about a six-hour period;
wherein the therapeutic agent or a pharmaceutically-acceptable salt thereof is selected from the group consisting of doxycycline, donepezil, ivermectin, risperidone, cetirizine, and rosuvastatin, or a pharmaceutically-acceptable salt thereof.
2. The gastric residence system of claim 1 , wherein the system releases about 30% to about 70% of the therapeutic agent or pharmaceutically-acceptable salt thereof within a time of about 40% to 60% of the effective release period.
3. The gastric residence system of claim 1 , wherein the system releases greater than about 70% of the therapeutic agent or pharmaceutically-acceptable salt thereof within a time of about 90% of the effective release period.
4. The gastric residence system of claim 1 , wherein the release of the therapeutic agent or pharmaceutically-acceptable salt thereof is measured in simulated gastric fluid.
5. The gastric residence system of claim 1 , wherein the release of the therapeutic agent or pharmaceutically-acceptable salt thereof increases by no more than about 40% in 40% ethanol/60% simulated gastric fluid versus the release over the same period of time in simulated gastric fluid.
6. The gastric residence system of claim 1 , wherein:
the therapeutic agent or a pharmaceutically-acceptable salt thereof comprises about 10% to about 35% of the carrier polymer-agent components.
7. The gastric residence system of claim 1 , wherein the release enhancer further comprises one or more compounds selected from the group consisting of an acrylate polymer, an acrylate co-polymer, a polydioxanone-polyethylene glycol polymer, and polyvinylpyrrolidone.
8. The gastric residence system of claim 1 , wherein the dispersant further comprises one or more compounds selected from the group consisting of a porous inorganic material, a polar inorganic material, a non-toxic metal oxide, an amphiphilic organic molecule, a polysaccharide, cellulose, a cellulose derivative, a fatty acid, a detergent, hydrophilic-fumed silica, hydrophobic colloidal silica, magnesium aluminum silicate, a stearate salt, calcium stearate, magnesium stearate, microcrystalline cellulose, carboxymethylcellulose, hypromellose, a phospholipid, a polyoxyethylene stearate, zinc acetate, alginic acid, lecithin, sodium lauryl sulfate, and aluminum oxide.
9. The gastric residence system of claim 1 , wherein the excipient further comprises a solubilizer.
10. The gastric residence system of claim 9 , wherein the solubilizer is selected from the group consisting of a polyalkylene oxide, a polyethoxylated castor oil, and a detergent.
11. The gastric residence system of claim 1 , wherein the stabilizer comprises about 0.1% to about 1% of the carrier polymer-agent components.
12. The gastric residence system of claim 11 , wherein the stabilizer comprises one or more compounds selected from the group consisting of an anti-oxidant, tocopherol, alpha-tocopherol, ascorbic acid, an ascorbate salt, a carotene, butylated hydroxyanisole, butylated hydroxytoluene, fumaric acid, an anti-microbial, a buffering substance, calcium carbonate, calcium lactate, calcium phosphate, sodium phosphate, and sodium bicarbonate.
13. The gastric residence system of claim 1 , wherein the polycaprolactone has an average M n of about 60,000 to about 100,000.
14. The gastric residence system of claim 1 , wherein the therapeutic agent or pharmaceutically acceptable salt thereof has a solubility in water of less than 1 mg/ml.
15. The gastric residence system of claim 9 , wherein the solubilizer is a copolymer of polyvinyl caprolactam, polyvinyl acetate, and polyethylene glycol.
16. A gastric residence system for administration to a patient, comprising:
at least one carrier polymer-agent component comprising:
a carrier polymer, wherein the carrier polymer comprises:
vinylpyrrolidone-vinyl acetate copolymer (VA64), wherein the at least one carrier-polymer-agent component comprises about 5% to about 10% of vinylpyrrolidone-vinyl acetate copolymer (VA64); and
polycaprolactone, wherein the carrier polymer-agent components comprise about 50.5% to about 89% polycaprolactone;
a therapeutic agent or a pharmaceutically-acceptable salt thereof blended into the carrier polymer;
a dispersant comprising silica (SiO2), wherein the at least one carrier-polymer-agent component comprises about 0.1% to about 1% of silica (SiO2);
an excipient, wherein the excipient comprises:
a release enhancer comprising poloxamer P407, wherein the at least one carrier-polymer-agent component comprises about 1% to about 15% of poloxamer P407; and
a stabilizer, wherein the at least one carrier-polymer-agent component comprises about 0.1% to about 1% of stabilizer;
wherein the at least one carrier polymer-agent component is linked to the gastric residence system by one or more coupling polymer components, wherein at least one of the one or more coupling polymer components is an elastomer;
wherein the gastric residence system is configured to have a compacted form in a container, suitable for administration orally or through a feeding tube; and an uncompacted form when released from the container;
wherein the gastric residence system is retained in the stomach for a residence period of between at least about 24 hours and about one month; and
wherein:
the system releases a therapeutically effective amount of the therapeutic agent over an effective release period; and
the system releases less than about 20% of the therapeutic agent or pharmaceutically-acceptable salt thereof within about a six-hour period;
wherein the therapeutic agent or a pharmaceutically-acceptable salt thereof is selected from the group consisting of doxycycline, donepezil, ivermectin, risperidone, cetirizine, and rosuvastatin, or a pharmaceutically-acceptable salt thereof.
17. The gastric residence system of claim 9 , wherein the solubilizer is a block copolymer of polyethylene glycol (PEG) and polypropylene glycol (PPG).
18. The gastric residence system of claim 1 , wherein the therapeutic agent or a pharmaceutically-acceptable salt thereof is risperidone.
19. The gastric residence system of claim 1 , wherein:
the carrier polymer-agent components comprises about 35% of the therapeutic agent or a pharmaceutically-acceptable salt thereof,
the carrier-polymer-agent components comprises about 0.5% of silica (SiO2),
the carrier-polymer-agent components comprises about 3% of poloxamer P407,
the carrier-polymer-agent components comprises about 0.5% of stabilizer;
the carrier-polymer-agent components comprises about 5% of vinylpyrrolidone-vinyl acetate copolymer (VA64);
the remaining balance of the carrier-polymer-agent components comprises polycaprolactone.
20. The gastric residence system of claim 1 , wherein the stabilizer comprises tocopherol and/or alpha-tocopherol.
21. The gastric residence system of claim 16 , wherein the stabilizer comprises tocopherol and/or alpha-tocopherol.
22. The gastric residence system of claim 19 , wherein the stabilizer comprises tocopherol and/or alpha-tocopherol.